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Abstract
Asthma is the most common chronic disease in childhood. The pathogenesis of
asthma is multifactorial and is thought to include environmental factors interacting
with genetics during pregnancy and in the first years of life. In the last decades, a
possible role of gut microbiota in allergic disease pathogenesis has been
demonstrated. Next generation sequencing techniques have allowed the identifica-
tion of a distinct microbiome in the healthy lungs. The lung microbiome is
characterized by the prevalence of bacteria belonging to the phylum Bacteroidetes
(mostly Prevotella and Veilonella spp) in healthy subjects and to the phylum
Proteobacteria in asthmatics (mostly Haemophilus, Moraxella, and Neisseria spp). In
asthma, as well as in other diseases, the lung microbiome composition changes due
to a disruption of the delicate balance between immigration and elimination of
bacteria. The lung microbiome can interact with the immune system, thus
influencing inflammation. Early infections with viruses, such as respiratory syncytial
virus, may alter lung microbiome composition favoring the emergence of
Proteobacteria, a phylum which is also linked to severity of asthma and bronchial
hyperreactivity. Lastly, antibiotics may alter the gut and lung microbiota and
potentially disturb the relationship between microbiota and host. Therefore,
antibiotics should be prescribed with increasing awareness of their potential harmful
effect on the microbiota in young children with and without asthma. The potential
effects of probiotics and prebiotics on lung microbiome are unknown.
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1 | INTRODUCTION
Asthma is one of the most common chronic disease worldwide,
affecting almost 300 million people with a continuously increasing
prevalence.1 It is also the main chronic disease in childhood,
affecting 10% of children. A great effort is currently being focused
on the search for preventive strategies, which seems feasible based
on evidence suggesting that the onset of atopy and asthma may be
strictly connected to several events occurring in very early stages of
life. In particular, exposure to antibiotics during fetal and neonatal
period,2 being born by cesarean section,3 formula feeding, maternal
diet, and the variety of microbes one is exposed to may play a key
Abbreviations: 16S rRNA, 16S ribosomal RNA; BAL, broncho-alveolar lavage; COPD,
chronic obstructive pulmonary disease; NGS, next generation sequencing; RSV, respiratory
syncytial virus.
role.4 The mechanisms proposed by which these factors predispose
to asthma are numerous, but what seems be a common feature is
their effects on gut microbiota. Indeed, in the last decades many
papers have been published on the role of gut dysbiosis in the
pathogenesis of allergic diseases. The gut has probably been
thoroughly studied because collecting samples is relatively easy
compared to other bodily sites.5 However, researchers have recently
demonstrated that specific communities of bacteria are present also
in the lungs and that their composition may play a crucial role in the
development of asthma, as well as in the development of other
respiratory diseases. Studies on the human microbiota have been
complicated by a certain degree of confusion in terminology: with
the term “microbiota,” Authors usually refer to bacteria associated
with the human body, while with “microbiome” they refer to the
array of genomes of such microbes, as identified by next generation
sequencing (NGS) techniques. These terms are often used inter-
changeably, and sometimes to include all the microorganisms
associated to the human body, encompassing also viruses and fungi.
As the literature regarding the composition of lung bacterial
communities’ is based on NGS studies, in this work, as in the great
majority of the previous studies on this subject, we will refer to the
microbial communities of the lungs as “lung microbiome” (Table 1).6
1.1 | Does the lung have its own microbiome?
The theory that healthy lower airways are sterile is one of the dogmas
in the history of medicine: however, with the advent of NGS
techniques and their application in microbiology, this hypothesis has
been reconsidered due to the frequent detection of bacterial
communities in healthy lower airways, as well as in other body sites
formerly believed to be sterile.7 As very few of these bacteria, if any,
can be isolated in culture, this finding has two important consequen-
ces: (1) Traditional culture isolation techniques can no longer be
considered the gold standard for bacteria detection and identification.
(2) Most body sites probably have their own resident microbial flora.
New molecular techniques applied to bacteriology include amplifica-
tion, sequencing, and analysis of the gene encoding 16S ribosomal
RNA (16S rRNA), ie, a small nucleic acid present in multiple copies in
bacterial cells and highly conserved among prokaryoties. This gene can
be used as a bar-code for definition of phyla and genera in specific
databases and allows, therefore, taxonomic investigation of bacterial
communities6 (Figure 1). Hilty et al8 used NGS for the first time on
lower airways samples from human subjects. This study included 24
adults (5 with chronic obstructive pulmonary disease [COPD], 11 with
asthma and 8 healthy controls) and 20 children (13 with severe asthma
and 7 healthy controls), all in clinical stability.8 Nasal and pharyngeal
swabs were collected from all study subjects, 23 of whom also
underwent bronchoscopy with protected brushing and/or broncho-
alveolar lavage (BAL). Their results showed that bacteria belonging to
the phylum Bacteroidetes (Prevotella spp in particular) were present,
albeit in small amounts, in the airways of healthy subjects. These
microorganisms are Gram-negative anaerobic bacteria, that are part of
the normal oral and vaginal flora and are not easily isolated by culture.
In contrast, subjects with asthma and COPD harbored mainly
Proteobacteria, including Haemophilus, Moraxella, and Neisseria spp.
In addition to showing that sick and healthy individuals have a different
microbial flora, this work was the first to report that the bronchial tree
of healthy subjects is colonized by bacteria. Further studies confirmed
TABLE 1 Terminology used in this work
Microbiome The term refers to bacterial communities associated with the human body identified by molecular methods. While this term is often
used interchangeably with microbiota, sometime in a broader sense encompassing also viruses and fungi, in this review the term
refers to all the genomes of bacteria found in the human body, analyzed trough the sequencing of 16S rRNA gene.
Microbiota In the strict sense, the term refers to bacteria associated with the human body studied by traditional culture.
Virome In the strict sense, the term refers to viruses associated with the human body.
FIGURE 1 A, Bacteria taxonomy; B, Taxonomical classification of Escherichia coli as defined the hierarchical organization showed in (A)
this finding and evidenced that phylum Firmicutes (especially Veilonella
spp, but also Streptococcus spp) is also highly represented in healthy
individuals,9 showing that the lung microbiome is more dynamic but
less varied compared to the gut microbiome. It is now clear that lung
microbiome composition depends on the resident flora of the upper
airways, which, therefore, represents the main reservoir for lower
airways colonization.9–10 Recently, Dickson et al11 demonstrated that
the oropharynx microbiome is nearly identical to the one of the right
upper lung lobe, but differs from that found in the other lobes. This
could be explained by the fact that, for anatomical reasons, the right
upper lobe is the most susceptible to immigration of bacteria by
microaspirations, which are common also in healthy subjects.12–13 It is
therefore possible that bacteria reach the lower airways through
repeated microaspirations of oropharyngeal secretions and, to a lesser
extent, through diffusion from the mucosa or by direct inhalation.9 In
children, microaspirations also involve secretions from the nasophar-
ynx,14 that are facilitated by the peculiar anatomy of upper airways and
increased production of nasal secretions during childhood.9,15 Any bias
related to the risk of contamination by medical procedures was
excluded, demonstrating that the passage of the bronchoscope
through the upper airways did not significantly alter results.11,16 But
what happens once the oropharyngeal bacteria reach the lower
airways? Dickson et al17 developed the “adapted island model,” which
postulates that the composition of lung microbiome is determined by
three factors: (1) Migration of bacteria from the upper airways; (2)
Elimination of bacteria by mucociliary clearance, cough and host
defenses; and (3) Levels of bacterial replication driven by local growth
conditions, such as pH, nutrient availability, oxygen tension, and
presence, amount, and type of immune cells. In healthy subjects, the
lung environment is inhospitable, so that bacterial replication rates are
low. Consequently, the microbiome is transient and shaped by
continuous migration and purging of bacteria. Respiratory diseases
may change local conditions to the point of creating niches that favor
persistence and replication of bacteria. Supporting this notion, chronic
colonization by bacteria that are difficult to eradicate is frequently
observed during severe respiratory ailments in general, especially in
advanced stages.10,17–18 Taken together, these findings demonstrate
that the lower respiratory tract does have its own flora that may
change according to the individual health status.
1.2 | Lung microbiome and immune response
The role of the lung microbiome in pathogenesis and the natural
history of respiratory diseases is incompletely understood. A
growing body of evidences suggest that the lung microbiome plays
an important role in the development and homeostasis of the
immune response. As a consequence, it is conceivable that dysbiosis
might facilitate the onset of respiratory diseases19 and, at the same
time, that the immune response affects the composition of
pulmonary microbiome.20 In other words, interactions between
the host's immune system and lung microbiome may be crucial for
the development of allergy and asthma,21 as observed for the gut
microbiome.
In the mouse model, for example, members of the phylum
Bacteroidetes and, in particular, Prevotella spp, have been shown to
reduce pulmonary inflammation, neutrophil recruitment, and pro-
inflammatory cytokine production mediated by Toll-like receptor 2,
unlike Haemophilus influenzae, which has a proinflammatory influ-
ence.22 Moreover, it has been demonstrated that asymptomatic
human adults who exhibit lung microbiome with higher percentage of
taxa characteristic of the oral cavity have increased numbers of
inflammatory cells in the lower airways mucosa and higher levels of
exhaled nitric oxide.9 Furthermore, in humans, a continuous and
diverse exposure to bacteria in the first years of life has been
associated with reduced chances of subsequent development of
asthma and atopy.23 It is likely that such exposure occurs mainly at the
airways, which represent the widest surface of the human body
exposed to the external environment. Recently, a gut-lung axis has
been proposed, in analogy to the close relationship between the lung
and gut microbiome observed in the mouse model. In mice, the
microbial flora resident in the two body sites continuously commu-
nicates via blood circulation, allowing reciprocal modulation, brought
about by local immune response, and microbiome composition.20
1.3 | Lung microbiome and asthma
It is well known that viral infections of the lower airways in the first
3 years of life are associated with increased risk of developing
asthma in later years, especially when caused by respiratory syncytial
virus (RSV) and rhinovirus.24 However, only recently the lung
microbiome was proposed as having a causal role in the genesis and
maintenance of chronic inflammation of the airways. This hypothesis
stemmed from the previously cited work by Hilty et al.,8 performed
on asthmatic adults and children, and from yet other studies showing
a higher prevalence of phylum Proteobacteria, together with a
greater diversity in the bacterial composition of the lung micro-
biome, in both asthmatic children and adults, compared to healthy
individuals.7,8,20 It is interesting to note that, in a prospective study
carried out in 2007, 21% of the traditional cultures from
hypopharyngeal aspirates from 321 infants, still in good health but
at risk of asthma due to asthmatic mothers (cohort of the COPSAC
study), were positive forMoraxella catarrhalis, Haemophilus influenzae
(which are members of phylum Proteobacteria) and Streptococcus
pneumoniae, alone or in combination. The presence of these bacteria
was associated with an increased risk of episodic wheezing or
asthma at the age of 5.25 In 2015, the results of the first investigation
on the features of the nasopharyngeal microbiome in the first year of
life was published.26 Here, the 16S rRNA sequencing was used in a
birth cohort of 234 children at high risk for asthma/allergy (cohort of
the Childhood Asthma Study). Nasopharyngeal aspirates were
collected at multiple times in the first year of life from these
patients, both in healthy conditions or during respiratory infections.
The microbiome was found to be mainly composed by the
phyla Proteobacteria, Firmicutes, and Actinobacteria, but its percent-
age composition changed according to the health status: the genera
mostly present in patients with respiratory infections were,
again, Haemophilus, Streptococcus, and Moraxella spp; conversely,
Staphylococcus, Alloiococcus, and Corynebacterium spp were those
most common in health. Staphylococcus or Corynebacterium were the
first genera to appear after birth and, in general, were subsequently
replaced by Moraxella or Alloiococcus, along with the occasional and
transient presence of Moraxella, Streptococcus, and Haemophilus
during acute viral infections. Follow-up demonstrated that detection
of Streptococcus within the first 2 months of life is more common in
children who will later develop aeroallergen sensitization and it is a
predictor of asthma at the age of 5.26
Another study examined 33 healthy infants and 99 infants who
were assessed during respiratory infection. Analyses, which also
included detection of RSV, were performed on nasopharyngeal
specimens, pointing out that the microbiome changed during RSV
infection, showing an increase in Proteobacteria (Moraxella and
Haemophilus spp) and Streptococcus and Corynebacterium spp.27 The
authors conclude that the well-known higher risk to develop asthma
following RSV infection24 could be associatedwith the alteration in the
composition of the bacterial microbiome induced by RSV. Accordingly,
a recent clinical study where the nasopharyngeal microbiome of 106
children with RSV infection and 26 healthy infants was evaluated,
further confirmed the higher prevalence of Streptococcus pneumoniae
and Haemophilus influenzae during RSV infection.28 Moreover, the
transcriptome profiles of children with RSV infection and high levels of
Streptococcus pneumoniae and Haemophilus influenzae in the airways
were characterized by an increased expression of Toll-like receptor
genes as well as by activation of macrophages and neutrophils, which
were in turn associated with more serious clinical manifestations.28,29
The evidence accrued thus far suggests that an imbalance of the
respiratory microbiome favoring higher levels of the phylum
Proteobacteria and Streptococcus spp in the first years of life could
contribute to asthma pathogenesis. The dysbiosis could play both a
direct effect on the immune response and an indirect effect in
modulating concomitant viral infections.29
1.4 | Lung microbiome and asthma severity
Lung microbiome may also affect the clinical course of asthma.
Dozens of studies have confirmed that lung microbiome in
asthmatics under treatment with inhaled steroids and/or rescue
bronchodilators shows a higher prevalence of Proteobacteria, along
with a greater diversity in bacterial composition compared to healthy
subjects.30 Moreover, Huang et al31 took protected specimen
brushing samples from 65 adult subjects with mild asthma and
under suboptimal control (ie, with persistent symptoms on Asthma
Control Questionnaire after four weeks of standardized treatment
with inhaled fluticasone). They demonstrated that the prevalence of
Proteobacteria and the diversity of bacterial composition correlate
with bronchial hyperreactivity. In the same study, clarithromycin,
administered to 16 patients, reduced bronchial hyperreactivity
significantly, particularly in subjects with high bacterial diversity
prior to treatment. This suggests that the beneficial effect of
macrolides observed in some asthmatic patients is a combinatorial
result of their intrinsic anti-inflammatory properties, and the
antibiotic effect on the lung microbiome.
While the microbiome in subjects with severe asthma is also
significantly enriched in Actinobacteria,32 in patients with severe
steroid-resistant asthma Haemophilus parainfluenzae, proved to favor
steroid resistance in macrophages.33 New studies on lung microbiome
are expected to shed light onmany aspects of severe asthma, aswell as
on non-Th2-mediated asthma, which is typical of adults and is
characterized by predominantly neutrophilic inflammation.34,35
There is no evidence so far that changes in lung microbiome are
involved in asthma exacerbations, but a hypothesis to explain what
happens at this level has been proposed. This is called “the dysbiosis-
inflammation cycle” model and suggests the existence of a
bidirectional interaction between lung microbiome and immune
response: according to this model, any inflammatory process (such as
the one evoked by a viral infection) would trigger a cascade of events
altering the factors regulating the microbiome composition, favoring
growth of some bacteria. This would further fuel inflammation and
immune responses, thus leading to a vicious circle eventually
exacerbating disease. Worsening of the disease, therefore, would
not be due to acute infection by a single bacterium emerging from
the microbiome, but rather to respiratory dysbiosis causing changes
in microbiome composition and dysregulation of inflammation. This
would explain why acute bacterial respiratory infections, caused by
overgrowth of a single bacterium, respond quickly to antibiotics,
while these drugs are ineffective during asthma exacerbations.17
1.5 | Future perspectives
Additional studies are warranted to gain further insight on the causal
role of bacterial colonization in the development of allergy and asthma.
It will be important to analyze the impact of short- and long-term
treatment with antibiotics, because antibiotics may alter the gut and
lung microbiome, thus interfering with their immunomodulatory
action.36,37 Notably, a few studies have shown some beneficial effects
of macrolides on bronchial inflammation,31 while others suggest that
antibiotics may play a causal role in the development of pediatric
asthma.38 Physicians should, therefore, be aware of these potential
risks and should prescribe these drugs only when necessary, especially
in the case of newborns and infants.20,29
Even if the evidence available seems to suggest a causal role of
changes in the composition of lung microbiome in asthma pathogene-
sis, whether such changes are primary or secondary to inflammation
has not yet been clarified sufficiently. In this respect, it will be
interesting to assess whether diet or probiotics and prebiotics
administration may modulate microbiome composition. Some studies
have evaluated the effects of these dietary supplements on the gut
microbiota and demonstrated some beneficial effects both in treating
and preventing asthma.36 Such data are not yet available for lung
microbiome.36
On a more general issue, another point to be clarified is whether
the bacterial genomes detected by molecular methods in the lower
airways belong to resident bacteria or are relics of past infections.
Culture isolation techniques would be the most suitable method to
ascertain whether bacteria from respiratory specimens are alive or not,
but the available techniques are still unable to reproduce the lung
habitat enabling their growth7: to this aim, new culture conditions and
media need to be developed soon. To advance our knowledge in the
near future, data obtained from transcriptional, proteomic and
metabolomic analyses will provide gene expression and metabolic
data deriving only from living cells.6
Inanycase, even ifwewerehighlightinggenesbelonging tobacteria
no longer present in the airways, this fact still helps interpret the effects
of their passage in the airways.39 Lastly, although most interest is
currently directed toward the bacterial microbiome, studies on virome
and mycobiome and their interactions with microbiome are also being
published.7,29 The evidence that is emerging, along with what was
already known about viruses, will possibly lead to a stronger concept of
asthma as a chronic inflammatory condition triggered, exacerbated and
maintained by the respiratory microbiome in a broad sense.39
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